Company: Eli Lilly and Co (Ireland) Ltd.
Legal category: Prescription. High tech reimbursable. Sport permitted.
Active ingredient: Ixekizumab 80mg/ml.
Description: Solution for injection in pre-filled syringe or pen.
Presentation: 1 syringe; 1 or 2 pens. Price available on request.
Indication: Treatment of moderate to severe plaque psoriasis in candidates for systemic therapy.
Pharmacology: Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity and specificity to interleukin 17A. Elevated concentrations of IL‑17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation. Neutralisation of IL‑17A by ixekizumab inhibits these actions.
Dosage: Adult: Administer by subcutaneous injection. Consider discontinuation if no response after 16 to 20 weeks. Avoid skin areas that show psoriasis. 160mg at Week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12. Maintenance, 80mg every 4 weeks. Elderly: As per adults. 75 years and older, limited data. Children: Under 18 years, not recommended.
Contraindications: Hypersensitivity to the active substance or to any of the excipients. Clinically important active infections. Pregnancy. Women should use contraception and not breast feed (assess risk/benefits) during treatment and ≤10 weeks after.
Special precautions: Caution: Inflammatory bowel disease, chronic infection (closely monitor if develops; suspend if serious or if no response to standard therapy). Latent tuberculosis (TB), consider anti-TB therapy prior to initiation. Discontinue immediately if hypersensitivity reactions occur.
Drug interactions: Not recommended: Live vaccines. CYP450 substrates with a narrow therapeutic index.
Adverse drug reactions: Upper respiratory tract infection, tinea infection, oropharyngeal pain, nausea, injection site reactions.
Full prescribing information and references available from Eli Lilly and Co (Ireland) Ltd. Telephone: (01) 664 0446. E-mail: ukmedinfo@lilly.com
The post Taltz ▼ appeared first on Irish Medical Times.